title: Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2.
abstract: Interleukin-2 (IL-2) is now registered for the treatment of renal cell carcinoma in a number of European countries. The subcutaneous (sc) route of administration is being used increasingly because of its better toxicity profile compared with higher dose intravenous (iv) protocols. We report here a patient who developed a lobular panniculitis at the site of sc IL-2 injection which prevents continuation of sc therapy. Subsequent administration of the same IL-2 dose by iv injection caused recurrence of the problem again necessitating discontinuation of IL-2 treatment.
authors.affiliation: Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands.
authors.forename: J W
authors.initials: JW
authors.lastname: Baars
authors.forename: J L
authors.initials: JL
authors.lastname: Coenen
authors.forename: J
authors.initials: J
authors.lastname: Wagstaff
authors.forename: P
authors.initials: P
authors.lastname: van der Valk
authors.forename: H M
authors.initials: HM
authors.lastname: Pinedo
mesh_terms: D000328:Adult; D001706:Biopsy; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000628:therapy; D015434:Panniculitis / Q000139:chemically induced* / Q000473:pathology; D012008:Recurrence; D012867:Skin / Q000473:pathology
chemical_list: D007376:Interleukin-2